| Expression pattern: |
UP |
| Associated gene: |
ILF3, TGF-beta2, IGF2BP2, IGF2BP3, METTL3, FTO |
| Associated microRNA: |
- |
| Biological function: |
promotes invasion, migration, EMT and metastasis in bladder cancer; serves as a potential diagnostic biomarker in serum exosomes |
| Molecular mechanism: |
circSLC38A1 binds ILF3, inhibits ILF3 ubiquitination/protein degradation to stabilize ILF3, and recruits ILF3 to activate transcription of TGF-beta2; m6A modification contributes to circSLC38A1 upregulation |
| Biological pathway or process: |
EMT (promotes); metastasis (promotes); ubiquitination (inhibits); m6A modification (promotes) |
| Detected method: |
Q
H
S
|
| Validation methods: |
circRNA-seq; RT-qPCR; Clinical Sample Validation; Cohort Study; Survival Analysis; ROC Analysis; Back-Splice Junction PCR / divergent primers PCR; RNase R Treatment; Sanger Sequencing; Actinomycin D / DRB Stability Assay; FISH / smFISH; ISH (In Situ Hybridization); RNA Pull-Down; RIP (RNA Immunoprecipitation); IF (Immunofluorescence); Western Blot; Transfection; Transwell Assay; Wound Healing Assay; In Vivo Animal Model; H&E Staining; MeRIP / MeRIP-seq; Bioinformatics Analysis; ChIP / ChIP-seq |
| Clinical significance: |
High tumoral circSLC38A1 levels correlate with shorter overall survival; serum exosomal circSLC38A1 distinguishes BC patients from healthy individuals (AUC=0.878) |
| Description: |
circSLC38A1 (hsa_circ_0000396), derived from SLC38A1, is up-regulated in bladder cancer tissues/cell lines and promotes migration, invasion, EMT and lung metastasis. Mechanistically, it binds the RBP ILF3, inhibits ILF3 ubiquitination to stabilize ILF3, and facilitates ILF3-dependent transcriptional activation of TGF-beta2; its upregulation is supported by m6A modification (METTL3/FTO-related). Clinically, high tumor expression predicts poorer OS, and serum exosomal circSLC38A1 shows diagnostic value (AUC 0.878). |
| Confidence score: |
0.9013 |